JUN 24, 2020 1:45 PM PDT

Gilead to Test Inhalable Remdesivir Against COVID-19

WRITTEN BY: Annie Lennon

Gilead has announced that it will soon start trials for an inhalable form of Remdesivir, the first drug to receive Emergency Use Authorization by the FDA to treat COVID-19.

Currently, Remdesivir is administered to patients intravenously. This means that it can only be used in clinical settings under medical supervision.

The new, inhalable version of the treatment could change this. To be administered via nebulizer, a device commonly used to treat asthma, Gilead hopes that the more convenient treatment will be used by patients at multiple stages of infection as opposed to just severe stages demanding hospitalization. 

 “Pretty much every outpatient urgent care clinic has them. You could potentially treat somebody on the spot who has a positive test” for the coronavirus “but may or may not have symptoms.” says Dr. Angela Rasmussen, a virologist at Columbia University. 

Starting this week, healthy volunteers will be screened for Phase I trials of the inhalable treatment to check its safety. If all goes to plan, patients infected with COVID-19 may then be able to begin trials with the treatment from August. 

As antivirals are thought to be most effective during the early stages of infection, Gilead hopes that the convenience of administering the drug via nebulizer may mean it can curb the virus earlier on. 

“If you could get rid of the virus before they develop those disease symptoms, you would probably have better clinical outcomes across many patients,” says Dr. Rasmussen.

Although nebulizers generally pose few problems to patients, they have been known to irritate some people’s airways. Moreover, previous experiments for nebulizer treatments for gene therapy and insulin have both failed. There is thus no guarantee that inhalable Remdesivir will work. 

Regardless of whether it works, Gilead plans on producing two million courses of Remdesivir by the end of the year. The company has also stated that it hopes to combine the antiviral with other drugs to enhance its effects. 


Sources: Medical Xpress, New York Times, Fierce Pharma

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 19, 2020
Cancer
Testing the Toxicity of CDK Inhibitors and Radiotherapy
AUG 19, 2020
Testing the Toxicity of CDK Inhibitors and Radiotherapy
Drug targets often focus on one thing, inhibiting or activating some critical function in a cell. Cancer drugs are no di ...
AUG 22, 2020
Drug Discovery & Development
New Class of Antibiotics Could Treat UTIs
AUG 22, 2020
New Class of Antibiotics Could Treat UTIs
At 11 million cases annually, urinary tract infections (UTIs) are the most common outpatient infections in the U.S., Sci ...
SEP 08, 2020
Space & Astronomy
New Drug May Allow Astronauts to Spend Years in Space
SEP 08, 2020
New Drug May Allow Astronauts to Spend Years in Space
Without gravity from Earth, muscles and bones tend to weaken quickly. To combat this, astronauts usually need to spend t ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 23, 2020
Drug Discovery & Development
FDA Gives Full Approval to Remdesivir to Treat COVID-19
OCT 23, 2020
FDA Gives Full Approval to Remdesivir to Treat COVID-19
The US Food and Drug Administration (FDA) has approved antiviral drug Remdesivir, sold under the name ‘Velkury&rsq ...
Loading Comments...